Cerapedics commenced full commercial availability of i-FACTOR®+ MATRIX for surgical implantation in Canada. This follows Health Canada approval in September.
i-FACTOR+ MATRIX uses small proprietary peptide technology supports bone growth through cell attraction, attachment and activation. i-FACTOR Peptide Enhanced Bone Graft was approved in the EU in 2008 and Australia in 2010 for orthopedic applications in the spine and extremities. In the U.S., i-FACTOR received premarket approval in 2015 for use in single-level anterior cervical fusion.
“We are excited to announce that i-FACTOR+ Matrix is now fully available in Canada through our distributor Surgi-One and can be used in both spine and general orthopedic applications,” said Glen Kashuba, Chief Executive Officer of Cerapedics. “Canada will be the first market offering the i-FACTOR+ MATRIX product, which leverages the clinically proven P-15 osteogenic cell-binding peptide combined with a collagen carrier for optimized handling.”
Cerapedics commenced full commercial availability of i-FACTOR®+ MATRIX for surgical implantation in Canada. This follows Health Canada approval in September.
i-FACTOR+ MATRIX uses small proprietary peptide technology supports bone growth through cell attraction, attachment and activation. i-FACTOR Peptide Enhanced Bone Graft was...
Cerapedics commenced full commercial availability of i-FACTOR®+ MATRIX for surgical implantation in Canada. This follows Health Canada approval in September.
i-FACTOR+ MATRIX uses small proprietary peptide technology supports bone growth through cell attraction, attachment and activation. i-FACTOR Peptide Enhanced Bone Graft was approved in the EU in 2008 and Australia in 2010 for orthopedic applications in the spine and extremities. In the U.S., i-FACTOR received premarket approval in 2015 for use in single-level anterior cervical fusion.
“We are excited to announce that i-FACTOR+ Matrix is now fully available in Canada through our distributor Surgi-One and can be used in both spine and general orthopedic applications,” said Glen Kashuba, Chief Executive Officer of Cerapedics. “Canada will be the first market offering the i-FACTOR+ MATRIX product, which leverages the clinically proven P-15 osteogenic cell-binding peptide combined with a collagen carrier for optimized handling.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
